117 related articles for article (PubMed ID: 28478639)
1. Concordance analysis between HER2 immunohistochemistry and in situ hybridization in non-small cell lung cancer.
Ko YS; Kim NY; Pyo JS
Int J Biol Markers; 2018 Jan; 33(1):49-54. PubMed ID: 28478639
[TBL] [Abstract][Full Text] [Related]
2. Concordance rate between HER2 immunohistochemistry and in situ hybridization in gastric carcinoma: systematic review and meta-analysis.
Pyo JS; Sohn JH; Kim WH
Int J Biol Markers; 2016 Feb; 31(1):e1-10. PubMed ID: 26349670
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathological significance and diagnostic accuracy of HER2 immunohistochemistry in colorectal cancer: a meta-analysis.
Pyo JS; Kang G; Park K
Int J Biol Markers; 2016 Dec; 31(4):e389-e394. PubMed ID: 27102863
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic Accuracy of BRAF Immunohistochemistry in Colorectal Cancer: a Meta-Analysis and Diagnostic Test Accuracy Review.
Pyo JS; Sohn JH; Kang G
Pathol Oncol Res; 2016 Oct; 22(4):831-7. PubMed ID: 27197524
[TBL] [Abstract][Full Text] [Related]
5. ALK immunohistochemistry for ALK gene rearrangement screening in non-small cell lung cancer: a systematic review and meta-analysis.
Pyo JS; Kang G; Sohn JH
Int J Biol Markers; 2016 Dec; 31(4):e413-e421. PubMed ID: 27338643
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathological significance and concordance analysis of c-MET immunohistochemistry in non-small cell lung cancers: A meta-analysis.
Pyo JS; Kang G; Cho WJ; Choi SB
Pathol Res Pract; 2016 Aug; 212(8):710-6. PubMed ID: 27465837
[TBL] [Abstract][Full Text] [Related]
7. A meta-analysis on concordance between immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) to detect HER2 gene overexpression in breast cancer.
Bahreini F; Soltanian AR; Mehdipour P
Breast Cancer; 2015 Nov; 22(6):615-25. PubMed ID: 24718809
[TBL] [Abstract][Full Text] [Related]
8. HER2 immunohistochemistry in endometrial and ovarian clear cell carcinoma: discordance between antibodies and with in-situ hybridisation.
Koopman T; van der Vegt B; Dijkstra M; Bart J; Duiker E; Wisman GBA; de Bock GH; Hollema H
Histopathology; 2018 Nov; 73(5):852-863. PubMed ID: 29989198
[TBL] [Abstract][Full Text] [Related]
9. Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation assay enables accurate assessment of HER2 genomic status in gastric cancer and has potential utility in HER2 testing of biopsy samples.
Yan B; Yau EX; Choo SN; Ong CW; Yong KJ; Pang B; Salto-Tellez M
J Clin Pathol; 2011 Oct; 64(10):880-3. PubMed ID: 21757431
[TBL] [Abstract][Full Text] [Related]
10. HER2 gene and protein expression status of breast carcinoma can be reliably tested on a single slide.
Chenard MP; Wissler MP; Weingertner N; Mathelin C; Bellocq JP
Virchows Arch; 2015 Aug; 467(2):169-75. PubMed ID: 25985875
[TBL] [Abstract][Full Text] [Related]
11. The role of human epidermal growth factor receptor 2 as a prognostic factor in lung cancer: a meta-analysis of published data.
Liu L; Shao X; Gao W; Bai J; Wang R; Huang P; Yin Y; Liu P; Shu Y
J Thorac Oncol; 2010 Dec; 5(12):1922-32. PubMed ID: 21155183
[TBL] [Abstract][Full Text] [Related]
12. Comparison of immunohistochemistry, four in situ hybridization methods and quantitative polymerase chain reaction for the molecular diagnosis of HER2 status in gastric cancer: a study of 55 cases.
Staněk L; Rozkoš T; Laco J; Ryška A; Petruželka L; Důra M; Dundr P
Mol Med Rep; 2014 Nov; 10(5):2669-74. PubMed ID: 25189406
[TBL] [Abstract][Full Text] [Related]
13. Validation and workflow optimization of human epidermal growth factor receptor 2 testing using INFORM HER2 dual-color in situ hybridization.
Lim SJ; Cantillep A; Carpenter PM
Hum Pathol; 2013 Nov; 44(11):2590-6. PubMed ID: 24075600
[TBL] [Abstract][Full Text] [Related]
14. Limited human epidermal growth factor receptor 2 discordance in metastatic breast cancer patients treated with trastuzumab, a population based study.
van Rooijen JM; de Munck L; de Graaf JC; Siesling S; de Vries EG; Boers JE
Eur J Cancer; 2014 Mar; 50(5):885-91. PubMed ID: 24491395
[TBL] [Abstract][Full Text] [Related]
15. A comparison study of HER2 protein overexpression and its gene status in breast cancer.
Md Pauzi SH; Saari HN; Roslan MR; Syed Khair Azman Jamalulil SNS; Tauan IS; Mohd Rusli FA; Aizuddin AN
Malays J Pathol; 2019 Aug; 41(2):133-138. PubMed ID: 31427548
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological significance and diagnostic approach of ROS1 rearrangement in non-small cell lung cancer: a meta-analysis: ROS1 in non-small cell lung cancer.
Yang J; Pyo JS; Kang G
Int J Biol Markers; 2018 Jun; ():1724600818772194. PubMed ID: 29874982
[TBL] [Abstract][Full Text] [Related]
17. Improving Selection Criteria for ALK Inhibitor Therapy in Non-Small Cell Lung Cancer: A Pooled-Data Analysis on Diagnostic Operating Characteristics of Immunohistochemistry.
Jiang L; Yang H; He P; Liang W; Zhang J; Li J; Liu Y; He J
Am J Surg Pathol; 2016 May; 40(5):697-703. PubMed ID: 26825369
[TBL] [Abstract][Full Text] [Related]
18. HER2 status in gastric cancer: a comparison of two novel in situ hybridization methods (IQ FISH and dual color SISH) and two immunohistochemistry methods (A0485 and HercepTest™).
Pala EE; Bayol U; Ozguzer A; Akman O
Pathol Res Pract; 2013 Sep; 209(9):548-54. PubMed ID: 23910175
[TBL] [Abstract][Full Text] [Related]
19. "HER2 immunohistochemistry inter-observer reproducibility in 205 cases of invasive breast carcinoma additionally tested by ISH" Answer to the statistical issue to avoid misinterpretation.
Casterá Redal C; Bernet Vegué L
Ann Diagn Pathol; 2020 Oct; 48():151566. PubMed ID: 32763505
[TBL] [Abstract][Full Text] [Related]
20. HER2 immunohistochemistry inter-observer reproducibility in 205 cases of invasive breast carcinoma additionally tested by ISH.
Casterá C; Bernet L
Ann Diagn Pathol; 2020 Apr; 45():151451. PubMed ID: 31955049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
